1 citations
,
March 2025 in “Journal of Investigative Dermatology” Metabolic issues may trigger lymphocytic cicatricial alopecia, and treatments targeting these issues could help.
May 2026 in “International Journal of Innovative Technologies in Social Science” PCOS is best managed with personalized lifestyle changes, medications, and sometimes surgery.
April 2026 in “Journal of Clinical Medicine” GLP-1 RAs may help wound healing but can also cause faster facial aging and skin issues.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
Methylene blue helps hair growth by protecting hair stem cells from stress.
January 2026 in “Quality in Sport” Semaglutide may help some skin disorders but can also cause skin issues.
A rash from semaglutide may be due to propylene glycol, not the drug itself.
October 2025 in “International Journal of Dermatology” GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
July 2025 in “Scientific Reports” RG and RJ gels speed up burn wound healing better than other treatments.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
February 2025 in “Journal of Neonatal Surgery” Combining antidiabetic drugs, hormonal therapies, and lifestyle changes can improve health in women with PCOS.
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Newer GLP-1 drugs like semaglutide may cause hair loss.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
August 2024 in “International Journal of Dermatology” New therapies and treatments for hair disorders, especially in curly hair, show promise.
May 2024 in “Psychiatric News” Weight-loss drugs are not linked to suicidal thoughts.
Early detection and comprehensive treatment of PCOS are crucial due to its long-term health impacts and associated risks.
February 2024 in “Journal of Education, Health and Sport” Different treatments for PCOS should be tailored to the individual, including lifestyle changes and various medications.
Women with Polycystic Ovary Syndrome (PCOS) have a higher risk of developing type 2 diabetes due to insulin resistance.
December 2019 in “Orvostudományi Értesítö” Lifestyle changes, medications, and fertility treatments can improve PCOS symptoms and prevent complications.
March 2026 in “Journal of Pharmaceutical Research” Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
11 citations
,
December 2022 in “Arterial Hypertension” New guidelines stress early diagnosis and lifestyle changes to manage metabolic syndrome and prevent complications.
1 citations
,
February 2025 in “Frontiers in Nutrition” Hawthorn-probiotic postbiotic may relieve constipation in elderly.
July 2024 in “Journal of Investigative Dermatology” JW0061 may be a new treatment for hair loss by promoting hair growth through WNT signaling.
November 2023 in “Open Repository of the University of Porto (University of Porto)” Community pharmacies and pharmacists play a crucial role in improving community health.
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
August 2025 in “Bioactive Materials” Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.
58 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Pioglitazone may help treat lichen planopilaris, but more research is needed.
3 citations
,
December 2023 in “International Journal of Nanomedicine” Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.